Страна: Канада
мова: англійська
Джерело: Health Canada
EPTACOG ALFA (ACTIVATED)
NOVO NORDISK CANADA INC
B02BD08
COAGULATION FACTOR VIIa
1MG
KIT
EPTACOG ALFA (ACTIVATED) 1MG
INTRAVENOUS
15G/50G
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0136061004; AHFS:
APPROVED
2013-11-26
_NIASTASE RT_ ® _ _ _Product Monograph _ Page 1 PRODUCT MONOGRAPH Schedule D NIASTASE RT ® eptacog alfa (activated) Activated Recombinant Human Blood Coagulation Factor VII Room Temperature Stable Lyophilized Powder 1.0 mg per vial (50 KIU/vial) 2.0 mg per vial (100 KIU/vial) 5.0 mg per vial (250 KIU/vial) 8.0 mg per vial (400 KIU/vial) Professed Coagulation Factor NOVO NORDISK CANADA INC. 101-2476 Argentia Road Mississauga, Ontario L5N 6M1 Canada CONTROL# 200866 DATE OF APPROVAL: November 10, 2017 _NIASTASE RT_ ® _ _ _Product Monograph _ Page 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................. 3 SUMMARY PRODUCT INFORMATION ......................................................... 3 DESCRIPTION .................................................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................... 3 CONTRAINDICATIONS .................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................. 4 ADVERSE REACTIONS .................................................................................... 8 DRUG INTERACTIONS ................................................................................... 15 DOSAGE AND ADMINISTRATION ............................................................... 16 OVERDOSAGE ................................................................................................. 21 ACTION AND CLINICAL PHARMACOLOGY ............................................. 21 STORAGE AND STABILITY .......................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................. 23 PART II: SCIENTIFIC INFORMATION ................................................................... 24 PHARMACEUTICAL INFORMATION .......................................................... 24 CLINICAL TRIALS ........... Прочитайте повний документ